Solid Biosciences (NASDAQ:SLDB) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating

Solid Biosciences (NASDAQ:SLDB - Get Free Report) was upgraded by research analysts at Cantor Fitzgerald to a "strong-buy" rating in a research note issued on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for Solid Biosciences' FY2025 earnings at ($1.60) EPS.

Other research analysts have also issued research reports about the company. Chardan Capital reiterated a "buy" rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Friday, March 7th. HC Wainwright upped their target price on Solid Biosciences from $16.00 to $20.00 and gave the company a "buy" rating in a report on Monday, March 10th. Finally, JPMorgan Chase & Co. dropped their price target on Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research report on Thursday, March 13th. Eight analysts have rated the stock with a buy rating and five have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $15.67.

Solid Biosciences Price Performance

Shares of SLDB opened at $2.55 on Tuesday. The company has a market cap of $197.63 million, a P/E ratio of -0.84 and a beta of 2.32. The stock has a fifty day moving average price of $3.63 and a 200 day moving average price of $4.26. Solid Biosciences has a 12 month low of $2.45 and a 12 month high of $10.46.

Institutional Trading of Solid Biosciences

Large investors have recently made changes to their positions in the stock. Monashee Investment Management LLC boosted its stake in Solid Biosciences by 248.6% during the 1st quarter. Monashee Investment Management LLC now owns 1,673,412 shares of the company's stock valued at $6,192,000 after purchasing an additional 1,193,412 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Solid Biosciences by 9,393.8% during the 4th quarter. JPMorgan Chase & Co. now owns 955,932 shares of the company's stock worth $3,824,000 after buying an additional 945,863 shares during the period. Redmile Group LLC bought a new position in shares of Solid Biosciences during the 4th quarter worth approximately $2,461,000. Dimensional Fund Advisors LP lifted its position in shares of Solid Biosciences by 270.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 264,069 shares of the company's stock worth $1,056,000 after buying an additional 192,714 shares during the period. Finally, Resolute Capital Asset Partners LLC acquired a new stake in Solid Biosciences during the 1st quarter valued at $555,000. Institutional investors own 81.46% of the company's stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.